UNITED STATES SECURITIES AND EXCHANGE COMMISSION  WASHINGTON, D.C. 20549  FORM 10-QSB/A  [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2004  [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from __________________ to __________________  Commission File Number 0-23957  MEDITECNIC, INC. (Exact Name of small business issuer as specified in its charter)  Nevada 87-0430532 (State or other Jurisdiction of I.R.S. Employer Identi- Incorporation or Organization fication No.)  24351 Pasto Road, #B, Dana Point, California 92629 (Address of Principal Executive Offices) (Zip Code)  (949) 489-2400 (Issuer's Telephone Number, including Area Code)  Indicate by check mark whether the Registrant (i) has filed all reports required to be filed by Section 13, or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (of for such shorter period that the Registrant was required to file such reports) and (ii) has been subject to such filing requirements for the past 90 days.  YesNo X Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. YesNo __X__ Indicate the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date.  Common Stock, par value  $.001 7,527,485 Title of Class Number of Shares outstanding at October 6, 2008 Transitional Small Business Format     Yes     No X      MEDITECNIC, INC. (A DEVELOPMENT STAGE COMPANY) BALANCE SHEET AS OF JUNE 30, 2004 AND DECEMBER 31, 2003  June 30 December 31 ASSETS 2004 2003  Current Assets Cash and Cash Equivalents $ 99,789 $ 161,658 Interest Receivable 37,245 38,741 Accounts Receivable 88,495 -- Prepaid Expenses 5,896 -- Marketable Securities 69,333 96,030 Total Current Assets $ 300,758 $ 296,429  Fixed Assets Vehicles 15,774 15,774 Office Furniture 17,871 17,871 Office Equipment 56,340 56,340 Data Processing Equipment 20,681 20,681 Equipment Installation 49,044 49,044 Organization Costs 26,254 23,449 185,964 183,159 Accumulated Depreciation (52,586) (130,608) Total Fixed Assets 133,378 52,551  Other Assets Patents 637,260 637,260 Research and Development (net of $341,483 and $282,434 amortization 111,078 62,120 Refundable Deposits 244,195 241,121 Total Other Assets 992,533 940,501  Total Assets $ 1,426,669 $ 1,289,481  LIABILIITES AND STOCKHOLDERS EQUITY Current Liabilities Accounts Payable 136,494 198,796 Accrued Payroll Taxes 13,826 18,114 Loans from Shareholders 395,053 719,472 Total Current Liabilities 545,373 936,382  Stockholders Equity Preferred Stock (1,000 shares issued and outstanding) 1 1 Capital Stock (7,527,485 issued and outstanding) 7,528 7,528 Additional Paid In Capital 3,495,072 3,495,072 Accumulated Deficit During the Development Stage (2,637,059) (3,165,980) Accumulated Other Comprehensive Income 15,755 16,477 881,296 353,099  Total Liabilities and Stockholders Equity $ 1,426,669 $ 1,289,481     See accompanying Notes to Financial Statements.


MEDITECNIC, INC. (A DEVELOPMENT STAGE COMPANY) STATEMENTS OF OPERATIONS CUMULATIVE FOR THE SIX FOR THE THREE FROM MONTHS ENDED MONTHS ENDED MARCH 24, 1998 JUNE 30 JUNE 30 JUNE 30 JUNE 30 TO Income 2004 2003 2004 2003 JUNE 30, 2004 Sales Turnover $ -- $ -- $ -- $ -- $ 258,814 Research and Development -- -- -- -- 357,332 Realization of Patents -- -- -- -- 90,734 Other Revenue 51 4,953 -- 2,476 14,081 Total Income 51 4,953 -- 2,476 720,961  Operating Expenses General and Administrative 5,000 21,190 1,000 10,595 264,205 Bank Charges 348 865 210 432 49,147 Audit Fees 28,260 5,000 28,260 2,500 58,735 Marketing and Advertising 11,787 2,931 7,502 1,465 23,667 Other Financial Charges -- -- -- -- 55,877 Legal and Honoraries Fees 28,845 5,781 7,920 2,890 53,831 Research and Development 15,610 -- 15,610 -- 1,065,454 Translation Fees -- -- -- -- 3,619 Patent Fees 36,885 90,361 13,749 45,180 558,359 Travel 2,599 14,571 2,599 7,285 104,588 Depreciation 9,128 8,108 4,774 4,054 139,736 Amortization 35,001 59,049 19,563 29,524 490,476 Vehicle Expense 79,733 -- 38,349 -- 858,710 Entertainment 1,334 8,629 (9) 4,314 39,412 Staff Research 2,604 115,770 900 57,885 5,407 Office Expense -- 3,309 -- 1,655 17,258 Small Materials and Supplies -- -- -- -- 69,490 Postage and Delivery 304 384 3 192 1,713 Insurance  Business 3,360 1,361 (1,147) 680 14,115 Promotions and Seminars 6,660 4,981 -- 2,490 82,630 Telephone 5,392 360 4,715 315 13,317 Office Rent 50,105 46,287 19,664 23,415 191,273 Utilities -- -- -- -- 318 Repairs and Maintenance -- 217 -- 109 1,741 Payroll Taxes 36,662 15,799 (487) 7,899 98,642 Total Operating Expenses 355,617 405,223 163,175 202,609 4,261,720  Net Operating Income (Loss) (355,566) (400,270) (163,175) (200,133) (3,540,759)  Other Income (Expense) Interest Income -- -- -- -- 38,607 Interest Expense (1,324) (2,237) (861) -- (15,432) Insurance Indemnities -- -- -- -- 10,568 Business Taxes (12,019) (1,039) (86) (520) (27,872) Total Other Income (Expense) (13,343) (3,276) (947) (520) 5,871  Net Income (Loss) $ (368,909) $ (403,546) $ (164,122) $ (200,653) $ (3,534,888)  Other Comprehensive Income (Loss) Gains (Losses) on Exchange Rates (12,398) (13,837) 4,119 (6,920) (52,047) Change in Value of Life Insurance -- -- -- -- 12,744 Gain (Loss) in Marketable Securities 40,216 14,555 -- 7,278 83,598 Net Other Comprehensive Income (Loss) 27,818 718 4,119 358 44,295  Net Income (Loss) per share $ (0.0490) $ (0.0536) $ (0.0218) $ (0.0267) $ (0.4696)  See accompanying Notes to Financial Statements      MEDITECNIC, INC. (A DEVELOPMENT STAGE COMPANY) STATEMENT OF CASH FLOWS CUMULATIVE FOR THE SIX FOR THE THREE FROM MONTHS ENDED MONTHS ENDED MARCH 24, 1998 JUNE 30 JUNE 30 JUNE 30 JUNE 30 TO 2004 2003 2004 2003 JUNE 30, 2004 Net Income $ (368,909) $ (403,546) $ (164,122) $ (200,653) $ (3,534,888)  Adjustments to reconcile net income to net cash provided by operating activities Depreciation 9,128 8,108 4,774 4,054 139,736 Amortization 35,001 59,049 19,563 29,524 490,476 Increase (decrease) in: Interest Receivable 23,633 (1,496) -- (748) (15,108) Accounts Receivable (2,928) 88,494 (6,814) 44,247 (2,928) Prepaid Expenses -- 5,460 -- 2,621 -- Inventory (104,116) -- (751) -- (104,116) Research and Development (26,200) (53,033) (34,477) (24,963) (543,768) Decrease (increase) in: Accounts Payable (13,618) 62,302 28,139 31,151 185,178 Accrued Liabilities (18,114) 4,287 -- 2,143 -- Other Comprehensive Income 27,818 718 4,119 358 44,295 Net Cash Provided (Used) By Operating Activities (438,305) (229,657) (149,569) (112,266) (3,341,123)  CASH FLOWS FROM INVESTING ACTIVITIES  Cash Used for Deposit 7,055 3,072 -- 1,536 (234,068) Surrender Value of Life Insurance -- -- -- -- -- Cash Used of Patent Acquisition -- -- -- -- (637,260) (Acquisition) Disposal of Fixed Assets (14,039) 2,805 (1,422) 1,403 (197,198) (Increase) decrease in Marketable Securities 70,606 (13,349) (184) (13,349) (25,424) Net Cash (Used) By Investing Activities 63,622 (7,472) (1,606) (10,410) (1,093,949)  CASH FLOWS FROM FINANCING ACTIVITIES  Loans From Shareholders 261,571 324,418 151,571 162,209 981,043 Sale of Common Stock -- -- -- -- 3,502,601 Net Cash (Used) By Financing Activities 261,571 324,418 151,571 162,209 4,483,645  NET INCREASE (DECREASE) IN CASH (113,112) 87,289 396 39,533 48,573  CASH AT BEGINNING OF PERIOD 161,685 12,500 48,177 60,256 --  CASH AT END OF PERIOD $ 48,573 $ 99,789 $ 48,573 $ 99,789 $ 48,573  Cash Paid for Interest 1,324 -- 861 -- 14,918


See accompanying Notes to Financial Statements.  MEDITECNIC, INC. (A Development Stage Company) NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED) JUNE 30, 2004   Item 1.       Comments  The accompanying financial statements are unaudited, but in the opinion of the management of the Company, contain all adjustments, consisting of only normal recurring accruals, necessary to present fairly the financial position at June 30, 2004, the results of operations for the three and six months ended June 30,  2004 and 2003, and the cash flows for the six months ended June 30, 2004 and 2003.  Reference is made to the Company's Form 10-KSB for the year ended December 31, 2003.  The results of operations for the six months ended June 30, 2004 are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2004.  Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION  The Company had no sales in 2004 or 2003. Our net loss was $____ and _____ for the three and six months ended June 30, 2004, compared to a net loss of  $______ and ________ for the three and six months ended June 30, 2003. The_______________________.  The Company invests cash in marketable securities. A portion of the Companys assets are valued in currencies other than the US dollar, primarily Swiss francs. We recognize gains and losses on the currency exchange rate changes from time to time.  The Company is in the research and development stage of its products   Research and development is carried out by a non affiliated entity, Meditecnic SA, on a contract basis.  The Company has an option to purchase all of the capital stock of Meditecnic SA for CHF 400,000 granted November 5, 1999, of which CHF 300,000 ($195,720) was paid in November 1999 and is accounted for as a deposit. We purchased a patent from Meditecnic in the 2001 quarter for $110,706, and loaned Meditecnic $243,528 in the 2001 quarter. The Company closed on the acquisition of Meditecnic on September 12, 2001. In addition the Company placed a CHF 60,000 deposit for the purchase of patents in December 1999 ($38,346) and a CHF 100,000 ($60,390) for the purchase of an additional patent in February 2000.  The Company had cash on hand and marketable securities of $_________ at June 30, 2004, which is believed to be sufficient to fund the Companys operations until at least the end of fiscal 2004.  Information included in this annual report includes forward looking statements, which can be identified by the use of forward-looking terminology such as may, expect, anticipate, believe, estimate, or continue, or the negative thereof or other variations thereon or comparable terminology. The statements in "Risk Factors" and other statements and disclaimers in this registration statement constitute cautionary statements identifying important factors, including risks and uncertainties, relating to the forward-looking statements that could cause actual results to differ materially from those reflected in the forward-looking statements.  Since we have not yet generated any revenues, we are a development stage company as that term is defined in paragraphs 8 and 9 of SFAS No. 7.   Our auditors have included an explanatory paragraph in their report on our financial statements, relating to the uncertainty of our business as a going concern, due to our lack of operating history or current revenues and competitive position.  We do not believe that conventional financing, such as bank loans, is available to us due to these factors.  We have no bank line of credit available to us.  Management believes that it will be able to raise the required funds for operations from one or more future offerings, in order to effect our business plan.  Our future operating results are subject to many facilities, including:  o     our success in developing our technology;  o     our ability to obtain customers for our devices;  o     the effects of competition;  o     our ability to obtain additional financing; and  o     other risks which we identify in future filings with the SEC.  Any or all of our forward looking statements in this annual report and in any other public statement we make may turn out to be wrong. They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Consequently, no forward looking statement can be guaranteed. In addition, we undertake no responsibility to update any forward-looking statement to reflect events or circumstances which occur after the date of this report.  PART II.  OTHER INFORMATION  Item 1. LEGAL PROCEEDINGS  -  None  Item 2. CHANGES IN SECURITIES - None  Item 3. DEFAULTS UPON SENIOR SECURITIES - None  Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS - None  Item 5. OTHER INFORMATION - None  Item 6. EXHIBITS --None   SIGNATURES  Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.   MEDITECNIC, INC.    Date: October 6, 2008 By:/s/ Luc Badel Luc Badel Treasurer (chief financial officer and accounting officer and duly authorized officer)